Gene therapy for thyroid cancer: current status and future prospects

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Thyroid cancer survival rates have stagnated despite conventional multimodality treatments.
• Novel therapeutic strategies, including gene therapy, are crucial for improving patient outcomes.
• Existing treatments include surgery, radioiodine, thyroxine suppression, chemotherapy, and radiotherapy.

Purpose of the Study:

• To review and evaluate various gene therapy approaches for thyroid cancer.
• To highlight the potential of sodium iodide symporter (NIS) gene transfer for radioiodine therapy.
• To assess the efficacy of combining different therapeutic genes for enhanced treatment.

Main Methods:

• Review of existing literature on gene therapy strategies for thyroid cancer.
• Evaluation of corrective, cytoreductive, and immunomodulatory gene therapy approaches.
• Focus on sodium iodide symporter (NIS) gene transfer and its application with radioiodine therapy ((131)I).

Main Results:

• Gene therapy approaches like p53 restoration and dominant-negative RET mutant expression show promise.
• Suicide gene therapy (HSV-tk/ganciclovir) and antiangiogenic therapy offer cytoreductive potential.
• NIS gene transfer can restore radioiodine accumulation in thyroid cancer cells, particularly beneficial for tumors lacking this activity.
• Combination of therapeutic genes enhances efficacy, suggesting a role in multimodality treatment for advanced thyroid cancer.

Conclusions:

• Gene therapy presents potentially curative novel therapeutic options for thyroid cancer.
• NIS gene transfer followed by radioiodine therapy is a promising strategy for specific thyroid tumor types.
• Combining gene therapies offers enhanced efficacy and a promising role in multimodality treatment for advanced thyroid cancer.